Clinical trials
HER2-negative Breast Cancer clinical trials
Below are recruiting her2-negative breast cancer clinical trials, each written for real people, not researchers. We’re tracking 264 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07242118Recruiting
Radiation therapy for older women with breast cancer
This trial tests a precise, high-dose radiation treatment (called SABR) for older women with early-stage breast cancer who choose not to have surgery. It aims to control the tumor with fewer side effects and may be an option if you have a small, ER+, HER2- tumor that hasn't spread to lymph nodes.
Kansas City, KansasAges 65 years+ - NCT07214532Recruiting
Using a blood test to guide breast cancer therapy
This study tests whether a blood test can help decide when to start additional hormone-blocking therapy for early-stage breast cancer. It aims to see if starting therapy only when the test detects cancer DNA is as effective as giving it to everyone.
Phoenix, ArizonaAges 18 years+ - NCT05332561RecruitingPhase 2
Personalized treatment after surgery for early breast cancer
This Phase 2 study checks whether adding a personalized (biomarker-matched) medicine after standard chemotherapy and surgery lowers the risk of breast cancer coming back. Your study drug choice depends on tumor test results (from your tumor’s genetics and immune markers).
Heidelberg, Baden-WurttembergAges 18 years+ - NCT05861830RecruitingPhase 3
Dalpiciclib plus hormone therapy after CDK4/6 treatment
This trial tests dalpiciclib together with hormone (endocrine) therapy in people with HR-positive, HER2-negative advanced breast cancer whose cancer has already responded poorly to a prior CDK4/6 inhibitor. It aims to see if this combination can better control the cancer after that earlier treatment has failed.
Beijing, Beijing MunicipalityAges 18–80 - NCT07380646RecruitingPhase 2
Leucogen to prevent low white blood cells from ribociclib in early breast cancer
This trial tests if Leucogen can prevent neutropenia (low white blood cells) caused by ribociclib, a targeted therapy for hormone receptor-positive, HER2-negative early breast cancer. It may help you stay on treatment without delays or dose reductions.
Hangzhou, ZhejiangAges 18 years+ - NCT06385990RecruitingPhase 2
Utidelone plus Capecitabine for residual triple-negative breast cancer
This trial tests a combination of two oral chemotherapy drugs (Utidelone and Capecitabine) for women with triple-negative breast cancer that did not fully disappear after standard chemo before surgery. The goal is to see if this treatment can lower the chance of the cancer coming back.
Changsha, HunanAges 18–70 - NCT06341621RecruitingPhase 3
Skipping chemo for ER+/HER2- breast cancer with 1–3 positive nodes
This trial tests whether skipping chemotherapy is safe for women with a specific type of early-stage breast cancer (ER-positive, HER2-negative) that has spread to 1–3 lymph nodes. Instead of chemo, you would receive a targeted pill called abemaciclib after standard hormone therapy.
ShanghaiAges 18–80 - NCT05879926RecruitingPhase 3
Testing chemo after hormone therapy in premenopausal early breast cancer
This Phase 3 trial checks whether adding chemotherapy after standard hormone-blocking treatment works better for some premenopausal women with early-stage, ER-positive, HER2-negative breast cancer. It targets patients with limited lymph node spread and a lower-to-intermediate tumor “recurrence” risk score.
Birmingham, AlabamaAges 18–60 - NCT06417801Recruiting
Study of ESR1 gene changes in blood in advanced breast cancer
This study looks for changes in the ESR1 gene in the blood of people with advanced HR+/HER2- breast cancer. It compares these blood test results with tumor tissue results to learn more about the cancer.
Salvador, Estado de BahiaAges 18–100 - NCT07358377RecruitingPhase 1
Combination therapy for HR-positive, HER2-negative cancer
This trial tests a new drug, HRS-6209, combined with other treatments for people with hormone receptor-positive, HER2-negative cancer. The goal is to see if the combination is safe and works well.
Bowral, New South WalesAges 18 years+ - NCT06671262RecruitingPhase 2
Immunotherapy plus radiation before breast cancer surgery
This trial tests combining two treatments—an immunotherapy drug (Toripalimab) and radiation—before surgery for a certain type of breast cancer (HR+, HER2-negative) that has spread to lymph nodes. The goal is to see if this combination helps shrink the tumor more than standard therapy alone.
Hangzhou, ZhejiangAges 18–85 - NCT06618287RecruitingPhase 1/Phase 2
Testing BMS-986507 for advanced lung and breast cancers
This study tests a new drug called BMS-986507, given in different combinations, for people with advanced solid tumors (lung cancer or breast cancer that has spread). It looks at safety, how the drug works in the body, and if it helps shrink tumors.
Birmingham, AlabamaAges 18 years+ - NCT07156253RecruitingPhase 1
Study of SYN818 with olaparib for advanced solid tumors
This trial is testing a new drug, SYN818, combined with olaparib for people with advanced solid tumors that have certain genetic changes (BRCA mutations or related DNA repair problems). It may be an option if you have ovarian or HER2-negative breast cancer and other treatments are no longer working.
Shanghai, Shanghai MunicipalityAges 18 years+ - NCT06640881RecruitingPhase 2
Repeat breast-conserving surgery with partial reirradiation
This trial tests a new approach for women whose breast cancer has returned in the same breast after earlier surgery and radiation. Instead of removing the whole breast, doctors will remove only the tumor again and give a small, focused dose of radiation before surgery, aiming to preserve the breast.
AmsterdamAges 50 years+ - NCT06222957Recruiting
How HER2 affects brown fat in breast cancer patients
This study looks at how a protein called HER2 affects brown fat activity in women with breast cancer. Brown fat helps burn calories and may influence treatment outcomes. You will be assigned to one of two groups based on your cancer's HER2 status, and the study will measure how your brown fat responds to cold.
CopenhagenAges 18 years+ - NCT07467330RecruitingPhase 3
Breast cancer trial: Adding capecitabine to standard treatment
This trial tests if adding a chemotherapy drug called capecitabine to the combination of dalpiciclib and hormone therapy works better than dalpiciclib and hormone therapy alone for advanced breast cancer that is hormone receptor-positive and HER2-negative. It is for people who have not had these treatments before.
Fuzhou, FujianAges 18 years+ - NCT06706570Recruiting
PIK3CA gene testing for breast cancer
This trial tests for a specific gene change (PIK3CA mutation) in your breast cancer cells. The results will help doctors decide if a targeted treatment is right for you. It's for people with hormone-receptor-positive, HER2-negative breast cancer that has spread and not yet been treated in that setting.
Milan, MIAges 18 years+ - NCT06607757RecruitingPhase 2
Capivasertib plus fulvestrant for high-risk lobular breast cancer
This trial tests adding capivasertib to fulvestrant for women with a certain type of breast cancer (invasive lobular carcinoma) that is hormone-receptor positive and has a high risk of coming back. The treatment is given before surgery to see if it works better than fulvestrant alone.
AugsburgAges 18 years+ - NCT06544577Recruiting
Elacestrant for advanced ER+/HER2- breast cancer with ESR1 mutation
This trial tests an oral drug called elacestrant in women whose ER+/HER2- breast cancer has worsened after at least one hormone therapy. It is for those with a specific genetic change (ESR1 mutation) and advanced or metastatic disease.
Qionghai, HainanAges 18 years+ - NCT05708235RecruitingPhase 2
Using blood test results to guide breast cancer treatment
This Phase 2 study tests whether doctors can use a blood test (ctDNA) to find breast cancer recurrence risk early and guide further treatment. Depending on your ctDNA result and tumor markers, you may receive standard hormone therapy or one of several additional treatment options.
A CoruñaAges 18 years+ - NCT06439771RecruitingPhase 2
Testing YL202 for advanced breast cancer
This trial tests a new drug called YL202 for people with advanced breast cancer. It is for those who have already tried certain targeted treatments (HER2 or TROP2 antibody-drug conjugates) and they stopped working. The goal is to see if YL202 can help shrink tumors or slow cancer growth.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT06666439Recruiting
Tracking lobular breast cancer with a blood test
This study is testing a new blood test that looks for cancer DNA to track how lobular breast cancer responds to treatment. It is for people whose cancer has spread and who have not yet started treatment for the spread.
Pittsburgh, PennsylvaniaAges 18 years+ - NCT07074106RecruitingPhase 2
Lower chemo with tumor-fighting cells for stage I-II breast cancer
This trial tests whether giving less chemotherapy is safe when patients have high levels of tumor-infiltrating lymphocytes (TILs) — a sign that the body's immune system is already fighting the cancer. It is for women with early-stage, triple-negative breast cancer.
BrasíliaAges 18 years+ - NCT07378306RecruitingPhase 2
Fasting-mimicking diet with chemo-immunotherapy for triple-negative breast cancer
This trial tests whether adding a special low-calorie diet (called a fasting-mimicking diet) to standard chemotherapy and immunotherapy can help treat triple-negative breast cancer before surgery. It aims to see if this combination makes the treatment work better.
Guangzhou, GuangdongAges 18–70
Hear when a new HER2-negative Breast Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for her2-negative breast cancer?
- Yes. Clin2 currently lists 264 recruiting her2-negative breast cancer studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a her2-negative breast cancer trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a her2-negative breast cancer trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
- Breast Cancer (Triple Negative Breast Cancer (TNBC))
- Breast Cancer Early Stage Breast Cancer (Stage 1-3)
- HR-positive, HER2-negative Advanced Breast Cancer
- Hormone Receptor Positive / HER2-negative Breast Cancer
- Metastatic Breast Cancer ( HER2 Negative)
- Triple Negative Breast Cancer
- HER2-positive Breast Cancer
- HR+/HER2- Breast Cancer
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.